Logo image of HNGE

HINGE HEALTH INC-A (HNGE) Stock Fundamental Analysis

NYSE:HNGE - New York Stock Exchange, Inc. - US4333131039 - Common Stock - Currency: USD

46.5  -0.45 (-0.96%)

After market: 47 +0.5 (+1.08%)

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to HNGE. HNGE was compared to 103 industry peers in the Health Care Providers & Services industry. While HNGE has a great health rating, there are worries on its profitability. HNGE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

HNGE had negative earnings in the past year.
In the past year HNGE had a positive cash flow from operations.
HNGE Yearly Net Income VS EBIT VS OCF VS FCFHNGE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2023 2024 0 -50M -100M

1.2 Ratios

HNGE has a Return On Assets of -1.67%. This is comparable to the rest of the industry: HNGE outperforms 44.66% of its industry peers.
HNGE's Return On Equity of -2.72% is in line compared to the rest of the industry. HNGE outperforms 50.49% of its industry peers.
Industry RankSector Rank
ROA -1.67%
ROE -2.72%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HNGE Yearly ROA, ROE, ROICHNGE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2023 2024 -5 -10 -15 -20 -25

1.3 Margins

The Gross Margin of HNGE (77.00%) is better than 90.29% of its industry peers.
HNGE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HNGE Yearly Profit, Operating, Gross MarginsHNGE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2023 2024 0 20 -20 40 -40 60

More info and screens

9

2. Health

2.1 Basic Checks

HNGE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, HNGE has about the same amount of shares outstanding.
HNGE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
HNGE Yearly Shares OutstandingHNGE Yearly Shares OutstandingYearly Shares Outstanding 2023 2024 20M 40M 60M
HNGE Yearly Total Debt VS Total AssetsHNGE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 8.06 indicates that HNGE is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 8.06, HNGE belongs to the best of the industry, outperforming 92.23% of the companies in the same industry.
HNGE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 8.06
ROIC/WACCN/A
WACC9.1%
HNGE Yearly LT Debt VS Equity VS FCFHNGE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 2.31 indicates that HNGE has no problem at all paying its short term obligations.
With an excellent Current ratio value of 2.31, HNGE belongs to the best of the industry, outperforming 81.55% of the companies in the same industry.
HNGE has a Quick Ratio of 2.26. This indicates that HNGE is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of HNGE (2.26) is better than 80.58% of its industry peers.
Industry RankSector Rank
Current Ratio 2.31
Quick Ratio 2.26
HNGE Yearly Current Assets VS Current LiabilitesHNGE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 88.96% over the past year.
Looking at the last year, HNGE shows a very strong growth in Revenue. The Revenue has grown by 33.37%.
EPS 1Y (TTM)88.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-228.89%
Revenue 1Y (TTM)33.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%49.71%

3.2 Future

HNGE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 110.38% yearly.
The Revenue is expected to grow by 23.32% on average over the next years. This is a very strong growth
EPS Next Y529.27%
EPS Next 2Y164.04%
EPS Next 3Y110.38%
EPS Next 5YN/A
Revenue Next Year33.79%
Revenue Next 2Y26.62%
Revenue Next 3Y23.32%
Revenue Next 5YN/A

3.3 Evolution

HNGE Yearly Revenue VS EstimatesHNGE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 200M 400M 600M
HNGE Yearly EPS VS EstimatesHNGE Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 0.2 0.4 0.6 0.8 1

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HNGE. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 61.13 indicates a quite expensive valuation of HNGE.
Compared to the rest of the industry, the Price/Forward Earnings ratio of HNGE is on the same level as its industry peers.
The average S&P500 Price/Forward Earnings ratio is at 36.52. HNGE is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 61.13
HNGE Price Earnings VS Forward Price EarningsHNGE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -100 -200 -300

4.2 Price Multiples

HNGE's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 43.71
EV/EBITDA N/A
HNGE Per share dataHNGE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4 5

4.3 Compensation for Growth

HNGE's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
HNGE's earnings are expected to grow with 110.38% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y164.04%
EPS Next 3Y110.38%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HNGE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HINGE HEALTH INC-A

NYSE:HNGE (7/17/2025, 8:04:01 PM)

After market: 47 +0.5 (+1.08%)

46.5

-0.45 (-0.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A N/A
Earnings (Next)08-05 2025-08-05
Inst Owners7.79%
Inst Owner ChangeN/A
Ins Owners75.36%
Ins Owner Change-1528.14%
Market Cap3.63B
Analysts83.53
Price Target47.21 (1.53%)
Short Float %28.28%
Short Ratio1.7
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 61.13
P/S 9.29
P/FCF 43.71
P/OCF 41.9
P/B 8.27
P/tB 9.76
EV/EBITDA N/A
EPS(TTM)-0.15
EYN/A
EPS(NY)0.76
Fwd EY1.64%
FCF(TTM)1.06
FCFY2.29%
OCF(TTM)1.11
OCFY2.39%
SpS5
BVpS5.62
TBVpS4.76
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.67%
ROE -2.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 77%
FCFM 21.26%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 63.5%
Cap/Sales 0.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.31
Quick Ratio 2.26
Altman-Z 8.06
F-ScoreN/A
WACC9.1%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-228.89%
EPS Next Y529.27%
EPS Next 2Y164.04%
EPS Next 3Y110.38%
EPS Next 5YN/A
Revenue 1Y (TTM)33.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%49.71%
Revenue Next Year33.79%
Revenue Next 2Y26.62%
Revenue Next 3Y23.32%
Revenue Next 5YN/A
EBIT growth 1Y81.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y166.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y176.68%
OCF growth 3YN/A
OCF growth 5YN/A